Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: The public-private partnership includes the World Health Organization, UNICEF, the Bill & Melinda Gates Foundation and the World Bank, among others. The funding announcement was made after a meeting of GAVI’s board. GAVI said the investment, which it called an estimate, will be provided between now and 2025. Since the current outbreak in eastern Congo was identified last August, health officials have immunized more than 255,000 people with a recently licensed vaccine made by Merck. To date there have been nearly 3,200 confirmed Ebola cases, including more than 2,200 deaths, in what has become the second deadliest Ebola outbreak in history. Dr. Ngozi Okonjo-Iweala, chair of Gavi’s board, called the creation of the Ebola vaccine stockpile a “historic milestone in humanity’s fight against this horrific disease.” GAVI said “a coordinating mechanism” to decide how and when vaccines will be used will be established with partner organizations. There are similar stockpiles for vaccines against yellow fever, meningitis and cholera. Those limited shots are doled out to developing countries by WHO, UNICEF, the Red Cross and Doctors Without Borders after receiving technical advice from others. The Ebola vaccine stockpile will be available to all countries, but only developing countries will be able to get vaccines for free in addition to support for the logistical costs of mounting vaccination campaigns. Jason Nickerson, a humanitarian affairs adviser at Doctors Without Borders, said the new stockpile would change how officials respond to future Ebola outbreaks. “Knowing how many doses of the vaccine exist in the world, and then being able to get a supply of them to high-risk countries in a very quick way, gives us another tool to respond to these outbreaks,” he said. Earlier this year, the medical charity publicly called for an independent committee to oversee Ebola vaccination efforts in Congo, saying WHO sometimes used arbitrary criteria to determine who would get immunized. It said the fact that Ebola was continuing to spread despite the large number of people vaccinated was a damning assessment of the response. Containing this outbreak has been complicated by violence and misunderstandings in a part of Congo that had never reported an Ebola case before. Last week, response activities were suspended after attacks killed four Ebola responders, including a member of a vaccination team. Multiple rebel groups operate in eastern Congo and the region has been described as a war zone. WHO has warned continued attacks on health workers and Ebola clinics could undermine attempts to curb Ebola and prompt a resurgence of the disease. Claim: Vaccine group announces creation of Ebola vaccine stockpile.

Output: The vaccine alliance GAVI announced Thursday it would invest $178 million to create a global stockpile of about 500,000 Ebola vaccines, a decision that health officials say could help prevent future outbreaks from spiraling out of control.


Input: Consider Input: Paragraph: "Cost data for flibanserin is not provided. Some projection of cost should be available for any drug this far along in Phase III trials – and for which the company has already begun marketing campaigns. If not from the company, then from stock analysts. The story properly quantifies the reported benefits in absolute terms which allows the reader to see that they are small. (Results are described in Quality of Evidence comments.) In an interview a study researcher conceded that the absolute number of women reporting benefit was not large. The story provided statistics on common side effects including daytime sleepiness, dizziness, fatigue, anxiety, dry mouth, nausea and insomnia. These side effects resulted in 15% of those taking flibanserin vs 7% taking placebo withdrawing from the study. The story does a good job of presenting and evaluating the available evidence. Results are presented in absolute terms, for example that just under one third of women taking flibanserin reported improvement in sexual distress/desire compared to approximately one fifth of women taking placebo. In contrast, these results were presented in relative terms by the manufacturer. Except for the headline, "" ‘Female Viagra’ May Treat Low Sexual Desire"", this story avoids disease mongering and notes that ""hypoactive sexual desire disorder"" in women is a controversial diagnosis. The text clarifies that while the popular press is dubbing flibanserin as the ""female Viagra"", it is not similar to Viagra or other drugs to treat erectile dysfunction. Conflicts of interest are disclosed. The story noted that the study researcher interviewed is a paid consultant for the drug manufacturer. An alternative point of view is provided by two independent experts, a psychologist and a sex-therapist. The independent sources comment on the role that personal relationships play in sexual desire and experience which was not addressed or acknowledged by the researchers. The story indicates that an alternative drug called the Intrinsa testosterone patch is available in Europe, but not in the U.S. The story also notes a difference between these dugs; Intrinsa is a hormonal treatment compared to flibanserin which is a non-hormonal. The story indirectly informs that reader that flibanserin is not available by noting that it is in phase III clinical trials and that the manufacturer is seeking FDA approval (despite early direct to consumer marketing campaigns). The story makes it fairly clear that this is a new treatment – also for a new and controversial diagnosis. The story was apparently based on research presented in abstract form at the annual clinical meeting of the American College of Gynecologists and Obstetricians, although this information has not been published in independently, peer-referred scientific journals. There is no direct evidence that it relied largely on a news release. In fact, the use of interviews with independent experts makes it clear that independent reporting took place." Claim: ‘Female Viagra’ May Treat Low Sexual Desire

Output: "This story reports on a investigational drug, flibanserin, that is being developed to treat what is a controversial diagnosis called ""hypoactive sexual desire"" in women. The popular press has dubbed this drug ""Female Viagra"" despite that fact that it has few similarities to drugs that treat erectile dysfunction. Preliminary research examining the drug’s efficacy in treating sexual distress and/or low sexual desire were presented at the May 2010 annual clinical meeting of the American College of Obstetricians and Gynecologists (ACOG). To place the story in context, previous reports from the manufacturer claimed that flibanserin resulted in ""clinically significant"" improvement in the number of sexually satisfying events reported by women taking the drug vs. those taking placebo, an absolute difference of 0.7 events per month. The story was detailed and did a good job of presenting information in absolute terms so that the reader could clearly see that reported benefits were small and of unknown clinical significance. Good reminders that this is a controversial diagnosis and that ""some experts see it as the medicalization of what is for many women a relationship issue."""


Input: Consider Input: Paragraph: According to a Today Show story posted on the MSNBC on December 23, 2008, this happened in September 2008 but some of the facts in the eRumor are wrong. Fourteen year old Chelsea Barton was born five weeks prematurely which resulted in developmental disabilities and serious health problems all her life. She was connected to life support at Presbyterian Hospital in Charlotte, North Carolina for pneumonia and the doctors had told her mother, Colleen Barton, that there was no hope for young Chelsea’s recovery. 14 year old Chelsea Barton at Presbyterian Hospital The Barton family gathered one last time in Chelsea’s hospital room to say their goodbyes and the order was giving to disconnect her from the life support system and “just let nature take its course.” According to the MSNBC Story, it appeared that Chelsea had another visitor just after the life support was disconnected. “As her mother waited for the girl to take her last breath, an image of bright light appeared on a security monitor. Within an hour, the dying girl began a recovery that doctors are at a loss to explain.”  Photo of strange light in the form of an angel from Colleen Barton’s cell phone Colleen Barton and other workers noticed an image of an angel in light on the security surveillance monitor near the hospital room door and Barton managed to capture the image with her cell phone camera. Barton told MSNBC that at first she thought that it was the angel of death coming to take her daughter but shortly afterwards Chelsea Barton started showing signs of improvement. According to the story, “It would be another two months before Chelsea finally left the hospital to return home, where she is about to celebrate her 15th birthday as well as Christmas. Her mother is convinced that Chelsea was saved by divine intervention.” Click here for MSNBC story with video updated 12/26/08 Comments Claim:  A forwarded email about the story of how a little girl at Presbyterian Hospital in Charlotte, North Carolina miraculously recovered from cancer after an angel was seen on a video surveillance monitor. 


Output: Teen Escapes Death After Hospital Video Captures Images of What the Family Believes Was an Angel